COVID-19 global pandemic: vaccines and new monoclonal antibodies, aspects to be clarified.
作者信息
Ferrara Francesco, Pianesi Laura, Vitiello Antonio
机构信息
Pharmaceutical Department, Usl Umbria 1, A.Migliorati Street, 06132, Perugia, Italy.
Pharmaceutical Department, Usl Umbria 2, Arcamone Street, 06034, Foligno,, (PG), Italy.
出版信息
Immunol Res. 2021 Apr;69(2):115-116. doi: 10.1007/s12026-021-09193-5. Epub 2021 Apr 15.
Abstract
摘要
相似文献
1
COVID-19 global pandemic: vaccines and new monoclonal antibodies, aspects to be clarified.新型冠状病毒肺炎全球大流行：疫苗与新型单克隆抗体，有待阐明的方面。
Immunol Res. 2021 Apr;69(2):115-116. doi: 10.1007/s12026-021-09193-5. Epub 2021 Apr 15.
2
The Need for a Global Network to Cope with Pandemics from Studies of the COVID Infection.从新冠病毒感染研究看建立全球网络应对大流行的必要性
Monoclon Antib Immunodiagn Immunother. 2020 Oct;39(5):157-159. doi: 10.1089/mab.2020.29002.tke. Epub 2020 Sep 30.
3
New generation of vaccines and convalescent plasma therapy for management of CoV-2: Perspectives from the UK and potential deployment in the current global pandemic.用于新冠病毒管理的新一代疫苗和恢复期血浆疗法：来自英国的观点及在当前全球大流行中的潜在应用
Transfus Apher Sci. 2021 Feb;60(1):103051. doi: 10.1016/j.transci.2021.103051. Epub 2021 Jan 11.
4
Plant-based vaccines and antibodies to combat COVID-19: current status and prospects.植物源疫苗和抗体抗击 COVID-19：现状和前景。
Hum Vaccin Immunother. 2020 Dec 1;16(12):2913-2920. doi: 10.1080/21645515.2020.1842034. Epub 2020 Dec 3.
5
Monoclonal Antibodies for Prevention and Treatment of COVID-19.用于预防和治疗新型冠状病毒肺炎的单克隆抗体。
JAMA. 2020 Jul 14;324(2):131-132. doi: 10.1001/jama.2020.10245.
6
COVID-19 Antibody Trials Have Begun.新冠病毒抗体试验已经开始。
JAMA. 2020 Jul 14;324(2):128. doi: 10.1001/jama.2020.11582.
7
COVID-19 vaccines: one step towards the beginning of the end of the global impact of the pandemic.新冠疫苗：迈向终结大流行全球影响开端的一步。
Anaesthesia. 2021 Apr;76(4):435-443. doi: 10.1111/anae.15365. Epub 2020 Dec 14.
8
Vaccines, therapeutics, and diagnostics for covid-19: redesigning systems to improve pandemic response.新冠病毒疫苗、疗法和诊断：重新设计系统以改善大流行应对。
BMJ. 2021 Nov 28;375:e067488. doi: 10.1136/bmj-2021-067488.
9
Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients.BNT162b2疫苗接种者中SARS-CoV-2感染和新冠肺炎的早期感染率降低情况。
Lancet. 2021 Mar 6;397(10277):875-877. doi: 10.1016/S0140-6736(21)00448-7. Epub 2021 Feb 18.
10
Antibodies may curb pandemic before vaccines.在疫苗问世之前，抗体可能会遏制疫情。
Science. 2020 Aug 14;369(6505):752-753. doi: 10.1126/science.369.6505.752.
本文引用的文献
1
Drugs acting on the renin-angiotensin system and SARS-CoV-2.作用于肾素-血管紧张素系统的药物与 SARS-CoV-2。
Drug Discov Today. 2021 Apr;26(4):870-874. doi: 10.1016/j.drudis.2021.01.010. Epub 2021 Jan 21.
2
SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice.SARS-CoV-2 刺突糖蛋白疫苗候选物 NVX-CoV2373 在食蟹猴中的免疫原性和在小鼠中的保护作用。
Nat Commun. 2021 Jan 14;12(1):372. doi: 10.1038/s41467-020-20653-8.
3
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.ChAdOx1 nCoV-19 疫苗（阿斯利康）对 SARS-CoV-2 的安全性和有效性：巴西、南非和英国四项随机对照试验的中期分析。
Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. Epub 2020 Dec 8.
4
[The effect of drugs on bronchial patency under conditions of respiratory musculature fatigue].[呼吸肌疲劳状态下药物对支气管通畅性的影响]
Fiziol Zh Im I M Sechenova. 1995 Feb;81(2):83-8.
Zotero 插件